Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that novel data from a preclinical study of its SynCon™ DNA vaccine against HIV were published in two separate scientific...
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin)...
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes...
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced the Phase I clinical study assessing Inovio's PENNVAX™-B DNA vaccine delivered using its proprietary electroporation technology in...